Table 2.
Fatty acid composition of duodenal lesions (weight %) from patients with familial adenomatous polyposis before and after treatment with Rofecoxib
| Placebo group | Rofecoxib group | 95% CI2 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| At baseline n = 16 | After intervention n = 12 | P valuea | At baseline n = 17 | After intervention n = 13 | P valuea | P valueb, c | Lower | Upper | |
| Fatty acids (weight %) in duodenal lesions | |||||||||
| Oleic acid | 20.2 ± 4.3 | 20.2 ± 2.8 | 0.3 | 18.7 ± 0.9 | 21.4 ± 3.6 | 0.04 | 0.04 | 0.2 | 6.7 |
| LA | 24.9 ± 3.3 | 25.3 ± 2.8 | 0.3 | 27.3 ± 2.3 | 25.3 ± 3.7 | 0.07 | 0.03 | −6.4 | −0.3 |
| MUFA | 21.2 ± 1.2 | 21.1 ± 2.8 | 0.3 | 19.6 ± 1.4 | 22.4 ± 3.9 | 0.04 | 0.03 | 0.3 | 6.9 |
| PUFA | 39.4 ± 6.0 | 40.4 ± 2.6 | 0.2 | 42.4 ± 2.0 | 39.2 ± 5.4 | 0.04 | 0.03 | −9.7 | −0.7 |
| Sum omega-6 fatty acids | 35.2 ± 5.1 | 36.2 ± 2.3 | 0.2 | 38.3 ± 2.2 | 35.3 ± 5.5 | 0.07 | 0.03 | −9.1 | −0.5 |
| Sum omega-9 fatty acids | 20.3 ± 4.3 | 20.2 ± 2.7 | 0.3 | 18.8 ± 1.4 | 21.4 ± 3.6 | 0.04 | 0.04 | 0.2 | 6.7 |
| EPA/DHA | 0.3 ± 0.1 | 0.4 ± 0.1 | 0.3 | 0.3 ± 0.01 | 0.4 ± 0.1 | 0.03 | 0.9 | −0.1 | 0.1 |
| EFA indexd | 2.0 ± 0.6 | 2.0 ± 0.4 | 0.3 | 2.2 ± 0.3 | 1.9 ± 0.5 | 0.04 | 0.04 | −0.9 | −0.1 |
| PUFA/(SAT + MUFA) | 0.7 ± 0.2 | 0.7 ± 0.1 | 0.3 | 0.7 ± 0.1 | 0.7 ± 0.1 | 0.04 | 0.03 | −0.2 | −0.1 |
| Sum omega-7 + omega-9 fatty acids | 4.4 ± 3.3 | 3.6 ± 1.4 | 0.3 | 3.2 ± 0.8 | 4.1 ± 2.2 | 0.3 | 0.03 | 0.3 | 6.9 |
Results are presented as mean ± standard deviation
a P value: between baseline and intervention
b P value: treatment effect: difference between end value and start value
cThe results for myristic acid, palmitic acid, palmitolic acid, stearic acid, ALA, eicosaenoic acid, eicosadienoic acid, AA, EPA, DHA, SAT, sum omega-3 fatty acids, omega-3/omega-6 fatty acids, palmitolic acid/palmitic acid, oleic acid/stearic acid and AA/LA, were not significant (all subjects) (data not shown in Table). After exclusion of the patients that were compliant for less than 8 months (n = 3), similar treatment effects were found for the same fatty acids: oleic acid (P = 0.01, 95% CI = 1.2; 7.8), LA (P = 0.046, 95% CI = −0.7; −0.1), MUFA (P = 0.009, 95% CI = 1.3; 8.1), PUFA (P = 0.02, 95% CI = −10.9; −1.3), omega-6 fatty acids (P = 0.03, 95% CI = −10.2; −0.7), omega-9 fatty acids (P = 0.01, 95% CI = −1.2; −7.8), EFA index (P = 0.01, 95% CI = 1.2; 7.8), omega-9 fatty acids (P = 0.01, 95% CI = −1.2; −7.8), EFA index (P = 0.01, 95% CI = −0.9; −0.1), PUFA/(SAT + MUFA) (P = 0.02, 95% CI = −0.3; −0.1), and sum omega-7 and omega-9 fatty acids (P = 0.01, 95% CI = 1.3; 8.1)
dEFA index: sum omega-3 fatty acids + sum omega-6 fatty acids/sum omega-7 fatty acids + sum omega-9 fatty acids